logo-loader
genedrive PLC

Genedrive PLC - New UK clinical guideline for MT-RNR1 testing

RNS Number : 8376O
Genedrive PLC
03 August 2026
 

3 August 2026

​

genedrive plc

("genedrive" or the "Company")

 

New UK clinical guideline published for MT-RNR1 genotype testing

 

-     Guideline recommends MT-RNR1 testing before aminoglycoside treatment and supports point-of-care testing in acute care settings

 

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, notes the publication of the UK clinical guideline "MT-RNR1 genotype testing for preventing aminoglycoside-mediated ototoxicity" in the British Journal of Clinical Pharmacology. The recommendations are intended to help prevent antibiotic-induced hearing loss ("AIHL"), which can occur following a single dose of an aminoglycoside antibiotic.

 

Developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics ("CERSI-PGx"), the guideline recommends MT-RNR1 genotype testing for people of all ages and genetic ancestries before aminoglycoside administration where results can be obtained within a clinically achievable timeframe, supporting broader clinical implementation of MT-RNR1 testing in acute care.

 

Specifically in relation to point-of-care testing, the guidelines state that it should be considered where available in all acute clinical settings, naming the Genedrive® MT-RNR1 ID Kit, which detects the m.1555A>G variant from a buccal swab and provides a result in approximately 26 minutes.

 

Dr Gino Miele, CEO of genedrive plc, said: "The publication of this new UK clinical guideline is an important step in the adoption of MT-RNR1 testing in acute care. The Genedrive® MT-RNR1 ID Kit is the only point-of-care MT-RNR1 test currently in routine clinical use in UK Neonatal Intensive Care Units, and these recommendations provide further support for wider NHS implementation of our test into routine acute care settings."

 

The guidance references the National Institute for Health and Care Excellence ("NICE") Early Value Assessment, which recommends the Genedrive® MT-RNR1 ID Kit for use in newborn babies while further evidence is generated. NICE's early economic modelling suggested that point-of-care testing with the Genedrive® MT-RNR1 ID Kit could be cost-saving and more effective than standard care. NICE has indicated that evidence from the PALOH-UK programme, which is addressing evidence gaps identified through the Early Value Assessment, will be considered as part of its planned review of the guidance.

 

 

genedrive plc

                                                                     +44 (0)161 989 0245

Gino Miele: CEO / Russ Shaw: CFO

                           https://investors.genedrive.com/s/e0025c 

 



Peel Hunt LLP (Nominated Adviser and Broker)

                                                                      +44 (0)20 7418 8900

James Steel




5654 & Company (Media & Investor Relations)

genedrive@5654.co.uk

Matthew Neal

+44 (0)7917 800 011

Melissa Gardiner

+44 (0)7757 697357

 

Subscribe to our news alert service: https://investors.genedrive.com/s/efea03 

 

About genedrive plc (http://www.genedrive.com).

 

genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company focused on rapid, point-of-care diagnostic tests to guide safe and effective drug prescription in emergency and acute care settings.

 

genedrive's proprietary technology platform enables clinicians to prescribe safer and more effective therapies based on a patient's genetic profile, supporting improved outcomes while reducing pressure on healthcare systems, lowering downstream healthcare costs through the prevention of avoidable complications and earlier, more effective intervention

 

The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not respond to the current standard of care, Clopidogrel, used to reduce risk of secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment decisions within actionable timeframes at the point of care.

 

Headquartered in Manchester, genedrive is focused on scaling UK-developed precision diagnostics within routine care and leveraging real-world evidence to support broader international adoption and commercial growth.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCWPUGAMUPQGCG
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Riccardo Lowi discusses Genedrive Plc

Riccardo Lowi, analyst at Capital Network on the launch preparation of Genedrive® HCV test with partner Sysmex on track, expect sales to start coming through in CY2018.

on 01/22/2018

4 min read